Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,742 DKK | +0.27% |
|
-3.56% | -18.22% |
06-28 | Would you like some more inflation? | ![]() |
06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 24.29 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 4.29 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.22% | 15.91B | - | ||
+17.12% | 121B | B+ | ||
+21.38% | 113B | B+ | ||
+18.52% | 26.02B | B | ||
-22.62% | 19.39B | B+ | ||
-18.35% | 15.09B | B | ||
-46.14% | 15.06B | A- | ||
+67.48% | 14.93B | C+ | ||
+6.96% | 13.85B | C+ | ||
+111.99% | 10.8B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GMAB Stock
- 0MGB Stock
- Ratings Genmab A/S